Welcome to our dedicated page for Lipocine news (Ticker: LPCN), a resource for investors and traders seeking the latest updates and insights on Lipocine stock.
Lipocine Inc. develops biopharmaceutical products using a proprietary technology platform for effective oral drug delivery. News about LPCN centers on clinical development of LPCN 1154, an oral brexanolone product candidate for postpartum depression, including trial progress, safety reviews and reported efficacy results.
Company updates also cover TLANDO, Lipocine’s oral testosterone replacement therapy, and related license, supply and distribution arrangements in multiple territories. Recurring financial news includes research and development spending, royalty revenue from TLANDO sales, pipeline prioritization and corporate presentations tied to the company’s oral-delivery programs.
Lipocine Inc. (NASDAQ: LPCN) announced enrollment completion of its Phase 2 LiFT study, investigating LPCN 1144 for non-cirrhotic NASH. The study involved 56 male patients and aims to evaluate liver fat reductions. Initial results are expected in January 2021, with further data in mid-2021. LPCN 1144 has previously shown promise in reducing liver fat without major tolerability issues in over 700 hypogonadal subjects. The company expresses optimism regarding the study amidst the COVID-19 pandemic.
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, has announced its participation in the 22nd HC Wainwright Annual Global Investment Conference from September 14-16, 2020. A corporate update will be presented on September 14 at 12 noon Eastern Time. Interested parties can view the presentation via webcast and register at hcwevents.com. Lipocine is focused on metabolic and endocrine disorders, with products like TLANDO aimed at restoring testosterone levels in men.
Lipocine Inc. (NASDAQ: LPCN) has announced that the FDA requires more time to review TLANDO's NDA, extending the anticipated PDUFA goal date of August 28, 2020. The FDA has not requested additional data and expects to finish its review in the coming weeks. TLANDO is an oral testosterone product for adult males with testosterone deficiency. Lipocine's pipeline also includes LPCN 1144, TLANDO XR, LPCN 1148, and LPCN 1107, focusing on metabolic and endocrine disorders.
Lipocine Inc. (NASDAQ: LPCN) reported financial results for Q2 2020, highlighting a net loss of $6.4 million, or ($0.13) per share, up from a $3.4 million loss in Q2 2019. R&D expenses rose to $2.3 million, driven by costs for LPCN 1144's Phase 2 study. General administrative costs increased to $2.0 million, largely due to legal fees from ongoing lawsuits. The company has $18.3 million in unrestricted cash as of June 30, 2020. Upcoming milestones include a PDUFA target date of August 28, 2020, for TLANDO's NDA and the initiation of the LPCN 1144 Phase 2 LiFT study.
Lipocine Inc. (NASDAQ: LPCN) announced the publication of its LPCN 1144 Liver Fat Study results, highlighting the effectiveness of LPCN 1144 in resolving non-alcoholic fatty liver disease (NAFLD) in hypogonadal males. The study, coauthored by experts from Virginia Commonwealth University and the University of Chicago, demonstrates a positive impact on hepatic steatosis and markers of liver injury. The company is also awaiting results from the ongoing Phase 2a LiFT clinical study, expected by the end of 2020, which further evaluates LPCN 1144's potential in treating non-cirrhotic NASH.
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, announced the dismissal of a shareholder derivative action, Wajda v. Patel, et al., by Vice Chancellor Laster in Delaware on July 31, 2020. The suit, filed on February 15, 2019, against the company's board, was dismissed due to the plaintiff's failure to demonstrate demand futility as per Delaware Chancery Rule 23.1. This development allows Lipocine to move forward without the burden of this litigation.
Lipocine Inc. (NASDAQ: LPCN) announced on July 13, 2020, that it has regained compliance with Nasdaq's minimum bid price requirement, as confirmed by a Nasdaq letter dated July 9, 2020. This development affirms that the company meets the criteria outlined in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. This compliance is critical for Lipocine's operations and investor confidence, as it avoids potential delisting threats that could negatively impact stock performance.